July 17, 2020Open Access

Dynamics of cell-free tumour DNA correlate with treatment response of head and neck cancer patients receiving radiochemotherapy

Key Points

Key points are not available for this paper at this time.

Abstract

Monitoring RCTX treatment-response using liquid biopsy in patients with locally advanced HNSCC is feasible. CtDNA can be seen as a surrogate marker of disease burden, tightly correlating with the gross tumour volume prior to the treatment start. The observed kinetic of ctDNA and cvDNA showed a negative correlation with time and treatment dosage in most patients.

KI fragen

Bookmark

View Full Paper

Cite This Study

Hilke et al. (Fri,) studied this question.

synapsesocial.com/papers/69dd4d017d97b7e86940cb88 https://doi.org/https://doi.org/10.1016/j.radonc.2020.07.027

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma.1999 · 775 citations
2Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer2015 · 1,139 citations
3Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma2019 · 552 citations
4Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries2018 · 87,815 citations
5Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma2016 · 100 citations

KI fragen

Bookmark

View Full Paper